Supply shortages of Pfizer's Jaquinus in Russian market

Russia has faced a shortage of Jaquinus/Xeljanz (tofacitinib), a drug to treat rheumatoid arthritis from US pharma giant Pfizer (NYSE: PFE), reports The Pharma Letter’s correspondent.

According to some Russian media reports, many of Russian pharmacies are currently selling off the last batches of the drug. The same has been confirmed by representatives of some largest federal clinics in Russia, according to which there have been serious problems with the supplies of the drug for at least four months.

Despite these reports, an official Pfizer spokesman has said that deliveries of Jaquinus to Russian pharmacies are carried out regularly. He recalls that contract production of the original drug has been carried out at the Polisan company in St Petersburg since 2016 and there are sufficient stocks of this drug in warehouses. Moreover, according to him, Pfizer is ready to consider increasing the volume of supplies if necessary. Polisan was not available for comments.